Cigna Group (CI) Stock Price & Analysis
Cigna Group (CI) rose 1.86% to USD 295 as of June 9, 2026 at 22:33 UTC, according to Nexqual real-time market data.
CI last closed at USD 289.61; the session ranged USD 289.38–295.02 on volume of 1,631,080 shares. Market capitalization is $78.04B, with a 52-week range of USD 239.51–338.89 (NYQ). Source: Nexqual, June 9, 2026 at 22:33 UTC.
Key Statistics (as of June 9, 2026 at 22:33 UTC)
| Price | USD 295 |
|---|---|
| Change | ▲ 1.86% (up) |
| Previous Close | USD 289.61 |
| Open | USD 290.8 |
| Day Range | USD 289.38 – 295.02 |
| 52-Week Range | USD 239.51 – 338.89 |
| Volume | 1,631,080 shares |
| Market Cap | $78.04B |
| Exchange | NYQ |
Technical Analysis (CI)
Nexqual's technical model rates CI "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 9, 2026 at 22:33 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 60.7 (neutral) |
| vs SMA50 | Above (USD 280.77) |
| MACD | 0.99 (positive) |
Analyst Ratings (CI)
Wall Street analysts rate CI "Buy" based on 24 analysts, with a mean price target of USD 340.92 (range USD 290–400), per Nexqual as of June 9, 2026 at 22:33 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 24 |
| Mean Target | USD 340.92 |
| High Target | USD 400 |
| Low Target | USD 290 |
| Buy / Hold / Sell | 20 / 4 / 0 |
Earnings (CI)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD 7.57 |
| Revenue Estimate | $70.12B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 7.79 vs est 7.61 ▲ beat |
| 2025-12-31 | USD 8.08 vs est 7.88 ▲ beat |
| 2025-09-30 | USD 7.83 vs est 7.64 ▲ beat |
| 2025-06-30 | USD 7.2 vs est 7.15 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:33 UTC.
Financials & Fundamentals (CI)
| Total Revenue | $277.89B |
|---|---|
| Revenue Growth (YoY) | +4.60% |
| Gross Margin | +9.15% |
| Operating Margin | +5.48% |
| Profit Margin | +2.26% |
| ROE | +16.27% |
| Debt / Equity | 72.81 |
| Current Ratio | 0.82 |
| Total Cash | $7.85B |
| Total Debt | $30.90B |
| Free Cash Flow | $6.92B |
Source: Nexqual, June 9, 2026 at 22:33 UTC.
Financial Health Score (CI)
Nexqual rates Cigna Group's overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 22:33 UTC.
| Growth | Solid — Revenue +11% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 9%, operating 5% |
| Balance Sheet | Mixed — $7.85B cash vs $30.9B debt |
| Cash Flow | Mixed — FCF $6.92B, slim 2.5% margin |
| Efficiency | Solid — ROE 16%, ROA 4.8% |
Ownership (CI)
| Insider Ownership | +1.44% |
|---|---|
| Institutional Ownership | +92.76% |
| Shares Outstanding | 264.53M |
| Float | 263.25M |
| Short % of Float | +2.58% |
Source: Nexqual, June 9, 2026 at 22:33 UTC.
Leadership (CI)
Cigna Group is led by David Michael Cordani (age 60), CEO & Chair of the Board, per Nexqual as of June 9, 2026 at 22:33 UTC.
| CEO & Chair of the Board | David Michael Cordani (age 60) |
|---|---|
| President, COO & Director | Brian Case Evanko C.F.A. (age 48) |
| Executive VP & CFO | Ann M. Dennison (age 54) |
| Executive Vice President, Chief Administrative Officer & Chief Human Resources Officer | Nicole Susan Jones (age 54) |
| Executive Vice President of Strategy & Business Development | F. Everett Neville (age 60) |
Major Backers & Investors (CI)
Notable institutional backers of Cigna Group include Dodge & Cox Inc., Massachusetts Financial Services Co., FMR, LLC, according to Nexqual as of June 9, 2026 at 22:33 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Inc. | 7.3% |
| Massachusetts Financial Services Co. | 4.38% |
| FMR, LLC | 4.14% |
| Sanders Capital, LLC | 3.89% |
| GQG Partners LLC | 2.27% |
| MFS SERIES TRUST I-MFS Value Fund | 2.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 15.98% |
| BlackRock | 9.83% |
| State Street | 5.83% |
| Geode Capital | 2.34% |
Source: Nexqual, June 9, 2026 at 22:33 UTC.
From Cigna Group's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Our formulary management   services support clients in establishing formularies that assist customers and physicians in choosing clinically appropriate, cost-effective drugs and prioritize access, safety and affordability. ▪ We administer specific formularies for our clients, including standard formularies developed by Express Scripts ® Pharmacy Benefit Services ("Express Scripts") and custom formularies in which we play a more limited role.
- Health System Services includes CuraScript SD by Evernorth ® , which is a specialty distributor of pharmaceuticals and medical supplies (including injectable and infusible pharmaceuticals and medications to treat specialty and rare or orphan diseases) directly to health care providers, including clinics and hospitals in the United States for office or clinic administration.
- We use these patents to protect our proprietary technological advances and to differentiate ourselves in the market.
- Our ability to deliver this broad array of health care services on either a standalone or combined basis between its two operating segments enables us to drive incremental growth.
Partnerships
- Through our clinical programs and partnership with EviCore, we guide care to the most appropriate settings, reducing unnecessary costs while preserving quality and service, and offer virtual care options, including MD Live, to improve convenience and access.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HUM | Humana Inc. | USD 363.18 | ▲ 3.74% |
| CNC | Centene Corporation | USD 66.21 | ▲ 6.22% |
| HCA | HCA Healthcare, Inc. | USD 374.9 | ▲ 0.74% |
| CAH | Cardinal Health, Inc. | USD 212.67 | ▲ 3.38% |
| MCK | McKesson Corporation | USD 784.23 | ▲ 1.1% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:33 UTC. This page is informational and not investment advice.